Results 111 to 120 of about 3,220 (195)

A multi-scale modeling framework for individualized, spatiotemporal prediction of drug effects and toxicological risk [PDF]

, 2013
International audienceIn this study, we focus on a novel multi-scale modeling approach for spatiotemporal prediction of the distribution of substances and resulting hepatotoxicity by combining cellular models, a 2D liver model, and whole body model. As a
Bucher, Joachim, Diaz Ochoa, Juan G., Mauch, Klaus, Niklas, Jens, Pery, Alexandre R.R., Zaldivar Comenges, José M.   +5 more
core   +4 more sources

EuroMix PBPK model for combined exposures

, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +1 more source

Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 568-578, February 2026.
Aims In haematopoietic cell transplantation (HCT), neutropenia resulting from myelosuppression is an expected endpoint following busulfan‐based conditioning. However, if prolonged, neutropenia can lead to complications like serious infection and death.
Beth Apsel Winger, Joseph W. Polli, Janel Long‐Boyle, Andrew Weber, Jordan Brooks, Jaimit Parikh, Valeriu Damian   +6 more
wiley   +1 more source

Comparing computational times for simulations when using PBPK model template and stand-alone implementations of PBPK models

Frontiers in Toxicology
IntroductionWe previously developed a PBPK model template that consists of a single model “superstructure” with equations and logic found in many physiologically based pharmacokinetic (PBPK) models. Using the template, one can implement PBPK models with different combinations of structures and features.MethodsTo identify factors that influence ...
Amanda S. Bernstein, Amanda S. Bernstein, Paul M. Schlosser, Dustin F. Kapraun   +3 more
openaire   +3 more sources

Pharmacokinetics of teicoplanin in paediatric patients—A systematic review of current literature

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 396-421, February 2026.
Background and Objective Teicoplanin is commonly used in children to treat gram‐positive infections and is sometimes used off‐label prophylactically in surgical or paediatric oncology settings. The pharmacokinetics (PK) of teicoplanin in children exhibit considerable variability, such as in critically ill children or those with renal impairment.
Noa E. Wijnen, Daan J. Touw, Kim Klein, Gertjan J. L. Kaspers, Paola Mian   +4 more
wiley   +1 more source

Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework

Pharmaceutics
Background/Objectives: Plasma levels of 4β-hydroxycholesterol (4β-OHC), a CYP3A-specific metabolite of cholesterol, are elevated after administration of CYP3A inducers like rifampicin and carbamazepine.
Aneesh V. Karkhanis, Matthew D. Harwood, Felix Stader, Frederic Y. Bois, Sibylle Neuhoff   +4 more
doaj   +1 more source

Physiologically Based Simulations of Deuterated Glucose for Quantifying Cell Turnover in Humans. [PDF]

, 2017
In vivo [6,6-(2)H2]-glucose labeling is a state-of-the-art technique for quantifying cell proliferation and cell disappearance in humans. However, there are discrepancies between estimates of T cell proliferation reported in short (1-day) versus long (7 ...
Becca Asquith, Christoph Niederalt, Derek Macallan, Derek Macallan, Julio Lahoz-Beneytez, Julio Lahoz-Beneytez, Stephan Schaller, Thomas Eissing   +7 more
core   +3 more sources

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 314-317, February 2026.
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug–drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI‐related parameters have often been considered a limitation for predicting PBPK‐DDIs.
Kunal S. Taskar, Pradeep Sharma, Karen Rowland Yeo   +2 more
wiley   +1 more source

Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 457-469, February 2026.
Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization. The pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy remains poorly characterized, despite active inflammatory bowel diseases (IBD) being the greatest risk factor for adverse ...
Zrinka Duvnjak, Robin Michelet, Casper Steenholdt, Ella S.K. Widigson, Cæcilie Skejø, João A. Abrantes, Wilhelm Huisinga, Mette Julsgaard, Charlotte Kloft   +8 more
wiley   +1 more source